Filing summary
Important identity mismatch: The supplied filing is Silverback Therapeutics, Inc.’s Form 10-Q, not an ARS Pharmaceuticals, Inc. filing. It covers the quarter ended March 31, 2021, and was signed May 13, 2021. Financial statements are unaudited; amounts below are in U.S. dollars unless noted.
Business context and reporting period
Silverback was a clinical-stage biopharmaceutical company developing tissue-targeted therapeutics using its ImmunoTAC platform. Its lead candidate, SBT6050, was in a Phase 1/1b trial for advanced or metastatic HER2-expressing solid tumors. SBT6290 and SBT8230 were in preclinical development. The company had no approved products and reported no revenue.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $12.239 million | $4.414 million; up 177% |
| General and administrative expense | $6.646 million | $0.828 million |
| Total operating expenses | $18.885 million | $5.242 million; up 260% |
| Net loss | $18.867 million | $5.279 million |
| Net loss per share, basic and diluted | $0.54 | $7.89; share counts differ substantially following the IPO and preferred-stock conversion |
| Net cash used in operating activities | $12.201 million | $7.628 million |
| Cash and cash equivalents at quarter-end | $374.205 million | $386.569 million at December 31, 2020 |
| Total liabilities | $13.650 million | $11.927 million at December 31, 2020 |
| Term loan | $0.495 million current, net, at March 31 | Final scheduled payment, including fee, made May 1, 2021 |
Operating margins are not meaningful because the company had no revenue. Cash, cash equivalents and restricted cash totaled $374.555 million at March 31, 2021. Stock-based compensation was $4.285 million, versus $0.047 million in Q1 2020.
Material changes versus the prior comparable period
- Net loss increased to $18.867 million from $5.279 million, mainly reflecting increased operating expenses.
- R&D expense rose by $7.825 million. The company attributed the increase principally to preclinical pipeline work, including SBT6290 and SBT8230, higher SBT6050 costs, and increased personnel expenses.
- G&A expense rose by $5.818 million, mainly due to greater personnel costs, including stock-based compensation, and costs associated with operating as a public company.
- Operating cash use increased by $4.573 million. Q1 2020 financing cash inflows included preferred-stock proceeds; Q1 2021 had no comparable preferred-stock proceeds.
Outlook, risks and unusual items
- Management expected operating losses to continue and expenses to increase as clinical and preclinical development advanced. The company did not provide revenue or earnings guidance.
- The MD&A said March 31 cash was expected to fund operating expenses and capital expenditures for at least 24 months. The liquidity note separately stated that available cash was sufficient for anticipated requirements for the 12 months following issuance of the financial statements. These runway statements differ and should be reconciled.
- Management said cash would not fund candidates through regulatory approval; additional capital would be needed. Potential financing could dilute shareholders, impose restrictive terms, or require licensing rights.
- Management reported pharmacodynamic-marker changes in the first SBT6050 dose cohort and anticipated an interim update from single-agent dose-escalation cohorts in the second half of 2021. It anticipated filing an IND for SBT6290 in Q4 2021.
- Risks include clinical-trial uncertainty and safety events, including potential anti-drug antibodies and hypersensitivity; patient enrollment and COVID-19-related delays; dependence on third-party manufacturers and service providers; regulatory and companion-diagnostic requirements; competition; and intellectual-property and financing risks.
- The company noted that some clinical sites had slowed or paused enrollment during the COVID-19 pandemic and that overseas drug-product shipments could be disrupted. It said the ultimate effects on development timelines and capital needs remained uncertain.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. It stated disclosure controls were effective as of March 31, 2021 and reported no material quarterly change in internal control over financial reporting.
Investor facts to verify
- Confirm the intended issuer: this document identifies Silverback Therapeutics, Inc. (ticker SBTX), not ARS Pharmaceuticals, Inc.
- Reconcile the filing’s 12-month liquidity statement with management’s at-least-24-month cash-runway estimate.
- Check the SBT6050 trial update and SBT6290 IND timing against subsequent disclosures; these were forward-looking expectations, not achieved milestones in this quarter.
- Review cash burn, equity-compensation expense, and the funding required to advance programs beyond early development.
- Confirm the May 1, 2021 term-loan payoff and assess continuing lease obligations and reliance on third-party manufacturing.